Key result
Rasburicase monotherapy significantly reduced tumor lysis syndrome-associated mortality compared to allopurinol (2.1% vs. 7.1%, p=0.047) in propensity score-matched patients with hematological malignancies.
Why the study?
The study aimed to determine whether a significant difference exists in TLS-associated mortalities in patients with hematological malignancies receiving rasburicase versus allopurinol monotherapy.
Does rasburicase reduce TLS-associated mortalities compared to allopurinol in patients with hematological malignancies?
Observational (n=282)
Yes
Does rasburicase reduce TLS-associated mortalities compared to allopurinol in patients with hematological malignancies?
In a real-world propensity-matched cohort of patients with hematological malignancies, rasburicase significantly reduced TLS-associated mortality compared to allopurinol.
Answers are grounded in this paper and cite their sources.
Rasburicase was associated with lower TLS mortality than allopurinol after matching; leaves open need for prospective confirmation.
PURPOSE: This retrospective, real-world (RW) study utilizing propensity score matching investigated tumor lysis syndrome (TLS)-related mortalities following anti-hyperuricemic (HU) monotherapy (allopurinol vs. rasburicase) in hematological malignancies. The study aim was to determine if a significant difference exists in the proportion of TLS-associated mortalities in hematological malignancy patients who received either rasburicase or allopurinol. METHODS: Following random selection of patient cases of rasburicase or allopurinol monotherapy, 141 in each group were PS-matched for TLS risk using 11 predictive covariates. RESULTS: Rasburicase-treated patients had significantly lower TLS-associated mortality (2.1% (n = 3) vs. 7.1% (n = 10) (p = 0.047)). CONCLUSIONS: Following successful PS matching of TLS-risk factors, this study suggests rasburicase statistically significantly reduces TLS-associated mortalities compared to allopurinol.
No takes yet. Share an insight, caveat, or question.
Cairo et al. (2025) conducted an observational in Hematological malignancies at risk of tumor lysis syndrome (n=282). Rasburicase vs. Allopurinol was evaluated on Tumor lysis syndrome (TLS)-associated mortality (p=0.047). Rasburicase monotherapy significantly reduced tumor lysis syndrome-associated mortality compared to allopurinol (2.1% vs. 7.1%, p=0.047) in propensity score-matched patients with hematological malignancies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: